Hemogenyx Pharmaceuticals PLC (LSE: HEMO) is an LSE listed, clinical-stage biotech focused on therapies for blood-related diseases and certain viral infections. The company is developing immunotherapy candidates for acute myeloid leukemia (AML) and other hematologic cancers, along with patient-conditioning approaches for bone marrow transplants, including a CDX bispecific antibody and a CAR-T program.   

Fundamental Highlights – Speculative Buy at GBX 725.00

Hemogenyx Pharmaceuticals reported steady progress in H1 2025, highlighted by the first human administration of its HG-CT-1 CAR-T therapy for acute myeloid leukaemia, with three patients treated and early signs of safety and potential efficacy observed. The company also received FDA clearance for a paediatric trial expansion and strengthened its manufacturing capabilities through strategic partnerships and grant support. Financially, it recorded a higher loss due to currency impacts but raised over £2 million to support ongoing development. Additionally, a collaboration with Cellin in Estonia may enable early revenue generation while advancing real-world clinical data collection.

Risk Assessment

Execution risk, regulatory risk, liquidity risk, thin volumes, Persistent Loss-Making Profile, volatility risk, etc.

Technical Summary

HEMO is currently trading above its key short- and long-term moving averages, which signals a sustained uptrend. The stock has delivered sharp price gains over recent months, supported by positive momentum indicators such as MACD, although elevated volatility suggests potential for short-term pullbacks within the broader upward trend.

Share Price Chart  

HEMO Daily Technical Chart, Source - Refinitiv

Conclusion

As per the above-mentioned price action and technical indicators analysis, a ‘Speculative Buy’ recommendation is given on the stock at the Current Market Price of GBX 725.00 as of 28^th April 2026 at 08:35 AM GMT+1.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 28 April 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and/or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.